Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rx Extended-Release Guaifenesin Must Exit Market By November, FDA Says

This article was originally published in The Tan Sheet

Executive Summary

Single-ingredient, extended-release prescription guaifenesin products must be removed from the market by the end of November if they have not been approved by FDA, the agency states in Feb. 25 letters to 66 marketers and distributors of the drugs

Related Content

Adams May Cough Up Humibid As Product Confusion Congests Sales
FDA Maps Pathways To Compliance At Unapproved Drugs Workshop
Adams’ Suit Could Delay ANDA For URL/Mutual’s Mucinex Generic
Mutual’s Mr. Mucus?
FDA Employs Carrot, Stick Under Unapproved Drug Enforcement Strategy
Adams Pulls Off Trade For Mucinex Complement
Guaifenesin warning letter
FDA Unapproved Drug Draft Compliance Policy Allows One-Year Grace Period
DESI drug compliance policy guide
Adams Mucinex Approval Spurs FDA Crackdown On Guaifenesin Products





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts